Advicenne S.A. (ALDVI.PA)
EUR 1.67
(0.12%)
EUR 1.67
(0.12%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 15.89 Million EUR | -7.13% |
| 2022 | 17.11 Million EUR | 38.34% |
| 2021 | 12.37 Million EUR | 33.79% |
| 2020 | 9.24 Million EUR | 21129.51% |
| 2019 | 43.56 Thousand EUR | -89.63% |
| 2018 | 419.9 Thousand EUR | -40.16% |
| 2017 | 701.67 Thousand EUR | 240.62% |
| 2016 | 206 Thousand EUR | -93.77% |
| 2015 | 3.3 Million EUR | 1892.77% |
| 2014 | 166 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 6.45 Million EUR | -60.09% |
| 2024 Q2 | 6.45 Million EUR | 0.0% |
| 2023 Q1 | 17.14 Million EUR | 0.14% |
| 2023 FY | 15.89 Million EUR | -7.13% |
| 2023 Q4 | 15.89 Million EUR | -1.7% |
| 2023 Q3 | 16.17 Million EUR | -5.67% |
| 2023 Q2 | 17.14 Million EUR | 0.01% |
| 2022 FY | 17.11 Million EUR | 38.34% |
| 2022 Q4 | 17.11 Million EUR | -0.59% |
| 2022 Q3 | 17.21 Million EUR | 33.39% |
| 2022 Q2 | 12.9 Million EUR | 0.02% |
| 2022 Q1 | 12.9 Million EUR | 4.31% |
| 2021 Q3 | 12.37 Million EUR | -8.86% |
| 2021 Q1 | 13.84 Million EUR | 49.74% |
| 2021 FY | 12.37 Million EUR | 33.79% |
| 2021 Q4 | 12.37 Million EUR | 0.02% |
| 2021 Q2 | 13.57 Million EUR | -1.99% |
| 2020 FY | 9.24 Million EUR | 21129.51% |
| 2020 Q4 | 9.24 Million EUR | 0.01% |
| 2020 Q1 | 8.79 Million EUR | 20080.43% |
| 2020 Q2 | 8.79 Million EUR | 0.01% |
| 2020 Q3 | 9.24 Million EUR | 5.18% |
| 2019 FY | 43.56 Thousand EUR | -89.63% |
| 2019 Q2 | 1.19 Million EUR | 0.0% |
| 2019 Q1 | 1.19 Million EUR | 183.63% |
| 2019 Q4 | 43.56 Thousand EUR | -96.71% |
| 2019 Q3 | 1.32 Million EUR | 11.17% |
| 2018 Q4 | 419.9 Thousand EUR | 0.0% |
| 2018 FY | 419.9 Thousand EUR | -40.16% |
| 2018 Q3 | 419.9 Thousand EUR | 62.76% |
| 2018 Q2 | 258 Thousand EUR | 0.0% |
| 2018 Q1 | 258 Thousand EUR | -63.23% |
| 2017 Q2 | 539 Thousand EUR | 0.0% |
| 2017 Q3 | 454 Thousand EUR | -15.77% |
| 2017 Q4 | 701.67 Thousand EUR | 54.55% |
| 2017 FY | 701.67 Thousand EUR | 240.62% |
| 2017 Q1 | 539 Thousand EUR | 161.65% |
| 2016 Q3 | 206 Thousand EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 Q4 | 206 Thousand EUR | 0.0% |
| 2016 FY | 206 Thousand EUR | -93.77% |
| 2015 FY | 3.3 Million EUR | 1892.77% |
| 2014 FY | 166 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -1343.778% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 64.436% |
| Adocia SA | 4.54 Million EUR | -250.132% |
| Aelis Farma SA | 2.04 Million EUR | -676.172% |
| Biophytis S.A. | 3.11 Million EUR | -410.961% |
| genOway Société anonyme | 5.51 Million EUR | -188.007% |
| IntegraGen SA | 642.28 Thousand EUR | -2374.933% |
| Medesis Pharma S.A. | 1.2 Million EUR | -1224.667% |
| Neovacs S.A. | 650 Thousand EUR | -2345.538% |
| NFL Biosciences SA | 39.2 Thousand EUR | -40447.917% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -264.879% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -710.884% |
| Sensorion SA | 1.24 Million EUR | -1180.994% |
| Theranexus Société Anonyme | 2.46 Million EUR | -545.99% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -307.799% |
| TheraVet SA | 1 Million EUR | -1488.648% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -130.177% |
| argenx SE | 15.35 Million EUR | -3.53% |
| BioSenic S.A. | 15.57 Million EUR | -2.074% |
| Celyad Oncology SA | 902 Thousand EUR | -1662.306% |
| DBV Technologies S.A. | 4.52 Million USD | -251.215% |
| Galapagos NV | 4.94 Million EUR | -221.521% |
| Genfit S.A. | 62.25 Million EUR | 74.465% |
| GeNeuro SA | 6.49 Million EUR | -144.844% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -4520.93% |
| Innate Pharma S.A. | 30.6 Million EUR | 48.064% |
| Inventiva S.A. | 25.61 Million EUR | 37.945% |
| MaaT Pharma SA | 5.42 Million EUR | -193.014% |
| MedinCell S.A. | 52.8 Million EUR | 69.894% |
| Nanobiotix S.A. | 41.66 Million EUR | 61.843% |
| Onward Medical N.V. | 16.3 Million EUR | 2.514% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -360.672% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 55.233% |
| Oxurion NV | 117 Thousand EUR | -13486.325% |
| Pharming Group N.V. | 123.65 Million EUR | 87.145% |
| Poxel S.A. | 40.14 Million EUR | 60.402% |
| GenSight Biologics S.A. | 1.04 Million EUR | -1416.794% |
| Transgene SA | 17 Thousand EUR | -93405.882% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.448% |
| Valneva SE | 132.76 Million EUR | 88.027% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |